Antimicrobial resistance (AMR) is in the news lately and for good reason. Diseases that were once easy to treat are becoming increasingly difficult to cure. But the largest contributor to AMR is a disease that rarely makes headlines – drug-resistant tuberculosis (DR-TB), the world’s only airborne drug-resistant infection. DR-TB makes up a third of the world’s burden of AMR and in 2017, there were more than half a million cases of DR-TB globally [1] – including some right here in the District of Columbia. It is estimated that two-thirds of individuals with DR-TB do not even know they are infected [2], posing a threat to their own health and to global health security.